LAVA Therapeutics NV

LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Peers: Merus N.V. ProQR Therapeutics NV Uniqure NV

Dive deeper

Financial snapshot data is not available right now.

Stock Price

Market Cap: $45.77 Million